Amikacin ototoxicity enhanced by Ginkgo biloba extract (EGb 761)

Basit Öğe Kaydı
dc.authoridMiman, Murat Cem/0000-0002-2139-9239
dc.authoridOZTURAN, ORHAN/0000-0002-6129-8627
dc.authorwosidMiman, Murat Cem/AAZ-4873-2020
dc.authorwosidOZTURAN, ORHAN/B-4984-2015
dc.contributor.authorMiman, MC
dc.contributor.authorOzturan, O
dc.contributor.authorIraz, M
dc.contributor.authorErdem, T
dc.contributor.authorOlmez, E
dc.date.accessioned2024-08-04T20:12:20Z
dc.date.available2024-08-04T20:12:20Z
dc.date.issued2002
dc.departmentİnönü Üniversitesien_US
dc.description.abstractAn animal study was realized to investigate the possible beneficial effect of EGb 761 as an antioxidant agent on amikacin ototoxicity by measuring distortion product otoacoustic emissions (DPOAEs). Twenty-eight adult rats were grouped equally as follows. Group amikacin: rats received amikacin 600 mg/kg/day intramuscularly between postnatal days (PND) 30 and PND44. Group amikacin/EGb 761: rats received amikacin 600 mg/kg/day intramuscularly between PND30 and PND44 and EGb 761 100 mg/kg/day orally between PND30 and PND50. Group EGb 761: rats received equivolume saline intramuscularly between PND30 and PND44 and EGb 761 100 mg/kg/day orally between PND30 and PND50. No treatment group: rats received nothing, Group amikacin was found to be affected only on the last measurement day of study (PND57). The frequencies greater than 2002 Hz were significantly reduced compared with the amplitudes of PND30 (P < 0.05). Group amikacin/EGb 761 was most and earliest affected by amikacin-induced ototoxicity. DPOAE amplitudes were found in this group to be decreased at 2-6 kHz starting on PND50. The results of Group EGb 761 and No treatment group were not significantly changed. For the DPOAE input/output amplitude thresholds, Group amikacin (P < 0.05) and Group amikacin/EGb 761 (P < 0.01) had significantly elevated thresholds on PND57, except at 5 kHz for Group amikacin (P = 0,06), According to the results of the study, EGb 761 may be regarded as a facilitating drug for the development of amikacin ototoxicity. The results of the present study may warn against concomitant use of aminoglycosides, specifically amikacin, with EGb 761. (C) 2002 Elsevier Science B.V. All rights reserved.en_US
dc.identifier.doi10.1016/S0378-5955(02)00385-4
dc.identifier.endpage129en_US
dc.identifier.issn0378-5955
dc.identifier.issue1-2en_US
dc.identifier.pmid12121745en_US
dc.identifier.scopus2-s2.0-0036019408en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage121en_US
dc.identifier.urihttps://doi.org/10.1016/S0378-5955(02)00385-4
dc.identifier.urihttps://hdl.handle.net/11616/93371
dc.identifier.volume169en_US
dc.identifier.wosWOS:000177025300011en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherElsevier Science Bven_US
dc.relation.ispartofHearing Researchen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectamikacinen_US
dc.subjectdistortion product otoacoustic emissionen_US
dc.subjectGinkgo biloba extracten_US
dc.subjectototoxicityen_US
dc.subjectpreventionen_US
dc.subjectraten_US
dc.titleAmikacin ototoxicity enhanced by Ginkgo biloba extract (EGb 761)en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu